Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1234.400
- -35.288-2.78%
12 Health Care Stocks Moving In Wednesday's Intraday Session
Sangamo Therapeutics Analyst Ratings
Apellis Pharmaceuticals Analyst Ratings
Carlyle, SK Capital Partners And Bluebird Bio Amend Merger Agreement; Stockholders May Elect To Receive Either $3/Share Plus CVR Of $6.84/Share In Cash Payable Upon Achievement Of A Net Sales Milestone Or $5/Share With No CVR
Cathie Wood Dumps Palantir As Stock Touches Peak Prices, Bails On Soaring Flying-Taxi Maker Archer Aviation
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
How Do Investors Really Feel About Agilent Technologies?
Baird Maintains Outperform on Editas Medicine, Lowers Price Target to $4
Editas Medicine Analyst Ratings
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Sangamo Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Sangamo Therapeutics Prices $23M Underwritten Offering Of 12.235M Shares Of Common Stock And Pre-Funded Warrants At $0.50 And $0.49 Respectively, Including Accompanying Warrants Exercisable At $0.75
12 Health Care Stocks Moving In Monday's After-Market Session
Sangamo Therapeutics Q1 GAAP EPS $(0.14) Misses $(0.13) Estimate, Sales $6.44M Miss $7.42M Estimate
Editas Medicine GAAP EPS of -$0.92 Misses by $0.35, Revenue of $4.66M Beats by $3.95M
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Has Been Granted To BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency
Forecasting The Future: 11 Analyst Projections For Intellia Therapeutics
Here Are the Major Earnings After the Close Today
Innovation, Pharma Profits Won't Suffer Under Trump Prescription Drug EO - White House